Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108


Interleukins-17 and 27 promote liver regeneration by sequentially inducing progenitor cell expansion and differentiation.

Guillot A, Gasmi I, Brouillet A, Ait-Ahmed Y, Calderaro J, Ruiz I, Gao B, Lotersztajn S, Pawlotsky JM, Lafdil F.

Hepatol Commun. 2018 Jan 30;2(3):329-343. doi: 10.1002/hep4.1145. eCollection 2018 Mar.


AJP-Cell Physiology begins landmark reviews in cell physiology: an editorial from the senior editors of AJP-Cell Physiology.

Delpire E, Hamilton KL, Hawke TJ, Isenberg JS, Lotersztajn S, Yuan JX, Adams JC.

Am J Physiol Cell Physiol. 2018 Jan 1;314(1):C1-C2. doi: 10.1152/ajpcell.00256.2017. Epub 2017 Nov 14. No abstract available.


Upregulation of Epac-1 in Hepatic Stellate Cells by Prostaglandin E2 in Liver Fibrosis Is Associated with Reduced Fibrogenesis.

Schippers M, Beljaars L, Post E, Lotersztajn S, Reker-Smit C, Han B, Munoz-Llancao P, Schmidt M, Poelstra K.

J Pharmacol Exp Ther. 2017 Nov;363(2):126-135. doi: 10.1124/jpet.117.241646. Epub 2017 Sep 1.


Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness.

Sharma S, Maras JS, Das S, Hussain S, Mishra AK, Shasthry SM, Sharma CB, Weiss E, Elkrief L, Rautou PE, Gilgenkrantz H, Lotersztajn S, Paradis V, de la Grange P, Junot C, Moreau R, Sarin SK.

Sci Rep. 2017 Jul 28;7(1):6816. doi: 10.1038/s41598-017-07161-4.


[Autophagy in chronic liver diseases: a friend rather than a foe?]

Gual P, Gilgenkrantz H, Lotersztajn S.

Med Sci (Paris). 2017 Mar;33(3):252-259. doi: 10.1051/medsci/20173303011. Epub 2017 Apr 3. Review. French.


Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.

Weiss E, Rautou PE, Fasseu M, Giabicani M, de Chambrun M, Wan J, Minsart C, Gustot T, Couvineau A, Maiwall R, Hurtado-Nedelec M, Pilard N, Lebrec D, Valla D, Durand F, de la Grange P, Monteiro RC, Paugam-Burtz C, Lotersztajn S, Moreau R.

J Hepatol. 2017 May;66(5):930-941. doi: 10.1016/j.jhep.2016.12.008. Epub 2016 Dec 28.


Autophagy in chronic liver diseases: the two faces of Janus.

Gual P, Gilgenkrantz H, Lotersztajn S.

Am J Physiol Cell Physiol. 2017 Mar 1;312(3):C263-C273. doi: 10.1152/ajpcell.00295.2016. Epub 2016 Nov 30. Review.


Chronic Exposure to Low Doses of Dioxin Promotes Liver Fibrosis Development in the C57BL/6J Diet-Induced Obesity Mouse Model.

Duval C, Teixeira-Clerc F, Leblanc AF, Touch S, Emond C, Guerre-Millo M, Lotersztajn S, Barouki R, Aggerbeck M, Coumoul X.

Environ Health Perspect. 2017 Mar;125(3):428-436. doi: 10.1289/EHP316. Epub 2016 Oct 7.


The Cannabinoid Receptor 2 Protects Against Alcoholic Liver Disease Via a Macrophage Autophagy-Dependent Pathway.

Denaës T, Lodder J, Chobert MN, Ruiz I, Pawlotsky JM, Lotersztajn S, Teixeira-Clerc F.

Sci Rep. 2016 Jun 27;6:28806. doi: 10.1038/srep28806.


Targeting cannabinoid receptors in hepatocellular carcinoma?

Mallat A, Lotersztajn S.

Gut. 2016 Oct;65(10):1582-3. doi: 10.1136/gutjnl-2016-312108. Epub 2016 Jun 24. No abstract available.


AJP-Cell Physiology begins a theme series on the control of the proteostasis network in health and diseases.

Chevet E, Pedeux R, Lotersztajn S.

Am J Physiol Cell Physiol. 2016 Aug 1;311(2):C163-5. doi: 10.1152/ajpcell.00130.2016. Epub 2016 May 25. No abstract available.


Statins Modulate Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 in Human Hepatic Myofibroblasts.

Mouawad CA, Mrad MF, El-Achkar GA, Abdul-Sater A, Nemer GM, Creminon C, Lotersztajn S, Habib A.

J Cell Biochem. 2016 May;117(5):1176-86. doi: 10.1002/jcb.25401. Epub 2015 Oct 18.


Macrophage autophagy protects against liver fibrosis in mice.

Lodder J, Denaës T, Chobert MN, Wan J, El-Benna J, Pawlotsky JM, Lotersztajn S, Teixeira-Clerc F.

Autophagy. 2015;11(8):1280-92. doi: 10.1080/15548627.2015.1058473.


Novel role for carbohydrate responsive element binding protein in the control of ethanol metabolism and susceptibility to binge drinking.

Marmier S, Dentin R, Daujat-Chavanieu M, Guillou H, Bertrand-Michel J, Gerbal-Chaloin S, Girard J, Lotersztajn S, Postic C.

Hepatology. 2015 Oct;62(4):1086-100. doi: 10.1002/hep.27778. Epub 2015 May 6.


Autophagy: a multifaceted partner in liver fibrosis.

Mallat A, Lodder J, Teixeira-Clerc F, Moreau R, Codogno P, Lotersztajn S.

Biomed Res Int. 2014;2014:869390. doi: 10.1155/2014/869390. Epub 2014 Aug 31. Review.


When autophagy chaperones liver metabolism.

Codogno P, Lotersztajn S.

Cell Metab. 2014 Sep 2;20(3):392-3. doi: 10.1016/j.cmet.2014.08.008.


Human hepatic stellate cells are not permissive for hepatitis C virus entry and replication.

Florimond A, Chouteau P, Bruscella P, Le Seyec J, Mérour E, Ahnou N, Mallat A, Lotersztajn S, Pawlotsky JM.

Gut. 2015 Jun;64(6):957-65. doi: 10.1136/gutjnl-2013-305634. Epub 2014 Jul 25.


AJP-cell begins a theme series on cellular mechanisms of endoplasmic reticulum stress signaling in health and disease.

Foufelle F, Lotersztajn S, Insel PA, Chevet E.

Am J Physiol Cell Physiol. 2014 Oct 1;307(7):C581. doi: 10.1152/ajpcell.00221.2014. Epub 2014 Jul 2. No abstract available.


ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis.

Fucho R, Martínez L, Baulies A, Torres S, Tarrats N, Fernandez A, Ribas V, Astudillo AM, Balsinde J, Garcia-Rovés P, Elena M, Bergheim I, Lotersztajn S, Trautwein C, Appelqvist H, Paton AW, Paton JC, Czaja MJ, Kaplowitz N, Fernandez-Checa JC, García-Ruiz C.

J Hepatol. 2014 Nov;61(5):1126-34. doi: 10.1016/j.jhep.2014.06.009. Epub 2014 Jun 16.


M2 kupffer cells promote hepatocyte senescence: an IL-6-dependent protective mechanism against alcoholic liver disease.

Wan J, Benkdane M, Alons E, Lotersztajn S, Pavoine C.

Am J Pathol. 2014 Jun;184(6):1763-72. doi: 10.1016/j.ajpath.2014.02.014. Epub 2014 Apr 5.


The metabolic syndrome and chronic liver disease.

Rosselli M, Lotersztajn S, Vizzutti F, Arena U, Pinzani M, Marra F.

Curr Pharm Des. 2014;20(31):5010-24. Review.


Aryl hydrocarbon receptor-dependent induction of liver fibrosis by dioxin.

Pierre S, Chevallier A, Teixeira-Clerc F, Ambolet-Camoit A, Bui LC, Bats AS, Fournet JC, Fernandez-Salguero P, Aggerbeck M, Lotersztajn S, Barouki R, Coumoul X.

Toxicol Sci. 2014 Jan;137(1):114-24. doi: 10.1093/toxsci/kft236. Epub 2013 Oct 23.


Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis.

Mallat A, Lotersztajn S.

Am J Physiol Cell Physiol. 2013 Oct 15;305(8):C789-99. doi: 10.1152/ajpcell.00230.2013. Epub 2013 Jul 31. Review.


M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease.

Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F, Pecker F, Tran A, Gual P, Mallat A, Lotersztajn S, Pavoine C.

Hepatology. 2014 Jan;59(1):130-42. doi: 10.1002/hep.26607. Epub 2013 Nov 20.


Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver.

Guillot A, Hamdaoui N, Bizy A, Zoltani K, Souktani R, Zafrani ES, Mallat A, Lotersztajn S, Lafdil F.

Hepatology. 2014 Jan;59(1):296-306. doi: 10.1002/hep.26598. Epub 2013 Nov 19.


Reply: To PMID 23728734.

Teixeira-Clerc F, Lotersztajn S.

Hepatology. 2014 Jan;59(1):353-4. doi: 10.1002/hep.26533. Epub 2013 Sep 30. No abstract available.


Cannabinoid signaling and liver therapeutics.

Mallat A, Teixeira-Clerc F, Lotersztajn S.

J Hepatol. 2013 Oct;59(4):891-6. doi: 10.1016/j.jhep.2013.03.032. Epub 2013 Apr 6. Review.


Reversion of hepatic stellate cell to a quiescent phenotype: From myth to reality?

Mallat A, Lotersztajn S.

J Hepatol. 2013 Aug;59(2):383-6. doi: 10.1016/j.jhep.2013.03.031. Epub 2013 Apr 6. No abstract available.


Pathophysiology of NASH: perspectives for a targeted treatment.

Marra F, Lotersztajn S.

Curr Pharm Des. 2013;19(29):5250-69.


AJP-Cell begins a theme series on tissue fibrosis.

Lotersztajn S, Insel PA.

Am J Physiol Cell Physiol. 2013 Feb 1;304(3):C215. doi: 10.1152/ajpcell.00405.2012. Epub 2012 Dec 19. No abstract available.


Adipose tissue macrophages: MR tracking to monitor obesity-associated inflammation.

Luciani A, Dechoux S, Deveaux V, Poirier-Quinot M, Luciani N, Levy M, Ballet S, Manin S, Péchoux C, Autret G, Clément O, Rahmouni A, Mallat A, Wilhelm C, Lotersztajn S, Gazeau F.

Radiology. 2012 Jun;263(3):786-93. doi: 10.1148/radiol.12111957. Epub 2012 Apr 20.


The liver X receptor in hepatic stellate cells: a novel antifibrogenic target?

Mallat A, Lotersztajn S.

J Hepatol. 2011 Dec;55(6):1452-4. doi: 10.1016/j.jhep.2011.05.018. Epub 2011 Jul 23. No abstract available.


Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice.

Louvet A, Teixeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, Zimmer A, Pecker F, Mallat A, Lotersztajn S.

Hepatology. 2011 Oct;54(4):1217-26. doi: 10.1002/hep.24524. Epub 2011 Sep 6.


The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings.

Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S.

Br J Pharmacol. 2011 Aug;163(7):1432-40. doi: 10.1111/j.1476-5381.2011.01397.x. Review.


Long term in vivo biotransformation of iron oxide nanoparticles.

Levy M, Luciani N, Alloyeau D, Elgrabli D, Deveaux V, Pechoux C, Chat S, Wang G, Vats N, Gendron F, Factor C, Lotersztajn S, Luciani A, Wilhelm C, Gazeau F.

Biomaterials. 2011 Jun;32(16):3988-99. doi: 10.1016/j.biomaterials.2011.02.031.


Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver.

Mukhopadhyay B, Cinar R, Yin S, Liu J, Tam J, Godlewski G, Harvey-White J, Mordi I, Cravatt BF, Lotersztajn S, Gao B, Yuan Q, Schuebel K, Goldman D, Kunos G.

Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6323-8. doi: 10.1073/pnas.1017689108. Epub 2011 Mar 7.


Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- mice.

Latasa MU, Gil-Puig C, Fernández-Barrena MG, Rodríguez-Ortigosa CM, Banales JM, Urtasun R, Goñi S, Méndez M, Arcelus S, Juanarena N, Recio JA, Lotersztajn S, Prieto J, Berasain C, Corrales FJ, Lecanda J, Avila MA.

PLoS One. 2010 Dec 29;5(12):e15690. doi: 10.1371/journal.pone.0015690.


Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration.

Teixeira-Clerc F, Belot MP, Manin S, Deveaux V, Cadoudal T, Chobert MN, Louvet A, Zimmer A, Tordjmann T, Mallat A, Lotersztajn S.

Hepatology. 2010 Sep;52(3):1046-59. doi: 10.1002/hep.23779.


Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis.

Servettaz A, Kavian N, Nicco C, Deveaux V, Chéreau C, Wang A, Zimmer A, Lotersztajn S, Weill B, Batteux F.

Am J Pathol. 2010 Jul;177(1):187-96. doi: 10.2353/ajpath.2010.090763. Epub 2010 May 27.


Endocannabinoids and their role in fatty liver disease.

Mallat A, Lotersztajn S.

Dig Dis. 2010;28(1):261-6. doi: 10.1159/000282100. Epub 2010 May 7. Review.


American Journal of Physiology-Cell Physiology initiates a series of articles around a theme: autophagy is the first theme.

Lotersztajn S, Insel PA.

Am J Physiol Cell Physiol. 2010 Apr;298(4):C775. doi: 10.1152/ajpcell.00011.2010. Epub 2010 Jan 13. No abstract available.


Cigarette smoke exposure: a novel cofactor of NAFLD progression?

Mallat A, Lotersztajn S.

J Hepatol. 2009 Sep;51(3):430-2. doi: 10.1016/j.jhep.2009.05.021. Epub 2009 Jun 10. No abstract available.


[Liver fibrosis: from pathophysiology to therapeutic openings].

Mallat A, Lotersztajn S.

Gastroenterol Clin Biol. 2009 Aug-Sep;33(8-9):789-98. doi: 10.1016/j.gcb.2009.05.004. Epub 2009 Jun 27. Review. French.


Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis.

Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, Nhieu JT, Belot MP, Zimmer A, Even P, Cani PD, Knauf C, Burcelin R, Bertola A, Le Marchand-Brustel Y, Gual P, Mallat A, Lotersztajn S.

PLoS One. 2009 Jun 9;4(6):e5844. doi: 10.1371/journal.pone.0005844.


Cannabinoid receptors as therapeutic targets in the management of liver diseases.

Mallat A, Lotersztajn S.

Drug News Perspect. 2008 Sep;21(7):363-8. doi: 10.1358/dnp.2008.21.7.1255306. Review.


The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy.

Defer N, Wan J, Souktani R, Escoubet B, Perier M, Caramelle P, Manin S, Deveaux V, Bourin MC, Zimmer A, Lotersztajn S, Pecker F, Pavoine C.

FASEB J. 2009 Jul;23(7):2120-30. doi: 10.1096/fj.09-129478. Epub 2009 Feb 26.


Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis.

Mallat A, Lotersztajn S.

Diabetes Metab. 2008 Dec;34(6 Pt 2):680-4. doi: 10.1016/S1262-3636(08)74604-4.


Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity.

Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, Wakkach A, Dahman M, Tordjman J, Clément K, McQuaid SE, Frayn KN, Huet PM, Gugenheim J, Lotersztajn S, Le Marchand-Brustel Y, Tran A, Gual P.

Diabetes. 2009 Jan;58(1):125-33. doi: 10.2337/db08-0400. Epub 2008 Oct 24.


The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis.

Perugorria MJ, Latasa MU, Nicou A, Cartagena-Lirola H, Castillo J, Goñi S, Vespasiani-Gentilucci U, Zagami MG, Lotersztajn S, Prieto J, Berasain C, Avila MA.

Hepatology. 2008 Oct;48(4):1251-61. doi: 10.1002/hep.22437.


Supplemental Content

Loading ...
Support Center